Yes, I absolutely do, and I think that is because of the entrance of generic competition into the market and bringing down the prices. That's exactly why that has been accomplished. We also have to remember there are still nine million people who have HIV/AIDS who do not have access to treatment. Those people are desperately in need. There is still a huge need, and the second-line, third-line drug issue is a big issue.
India is not going to be the solution to that. One of the big reasons is that many of those drugs are under patent in India. Due to its compliance with the WTO from the first of January 2005, it can no longer just produce many of those drugs under generic versions, so its prices will be higher.
Canada has a role to play in order to bring another player into the market, have their generic companies.... When Apotex came into the market, it forced Indian companies to go and make sure that their drugs were of adequate quality and get them pre-qualified with the WHO program. This was a hugely important aspect of what Apotex managed to do.
If the limitations are taken off, as would be the case under Bill C-393, we would be able to provide another player in the market, which would encourage competition.